<DOC>
	<DOC>NCT00510029</DOC>
	<brief_summary>The study will assess the safety, tolerability and pharmacokinetics of single intravenous (IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour infusion.</brief_summary>
	<brief_title>Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Generally healthy men and women of nonchildbearing potential (WONCBP), aged 18 to 50 years. Body Mass Index (BMI) range of 18 to 30 kg/m2. Blood serum creatinine levels less than or equal to the upper limit of normal. Exclusion Criteria Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease. Any history of clinically important cardiac arrhythmias and familial history of long QT syndrome or unexpected cardiac death. History of drug and alcohol abuse, positive HIV, HCV, and/or HBs Ag test, and any clinically important deviation from normal limits in physical examination, vital signs, 12lead ECGs, or clinical laboratory test results.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>